SREBF1 and glioblastoma: In glioblastomas that do not carry EGFR mutations, but instead have AKT pathway activation, silencing of SREBP1 or SREBP2 prevented xenograft growth, confirming the importance of fatty acid metabolism in tumour maintenance (Griffiths et al., 2013; Williams et al., 2013).